Literature DB >> 8027411

Metabolism of haloperidol: clinical implications and unanswered questions.

M W Tsang, R I Shader, D J Greenblatt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8027411

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN： 0271-0749            Impact factor:   3.153


× No keyword cloud information.
  6 in total

Review 1.  Pharmacokinetics of haloperidol: an update.

Authors:  S Kudo; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

2.  Population pharmacokinetics of haloperidol using routine clinical pharmacokinetic data in Japanese patients.

Authors:  Eiji Yukawa; Tsuyoshi Hokazono; Miho Yukawa; Ritsuko Ichimaru; Takako Maki; Kanemitsu Matsunaga; Shigehiro Ohdo; Motoaki Anai; Shun Higuchi; Yoshinobu Goto
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol.

Authors:  J G Shin; K Kane; D A Flockhart
Journal:  Br J Clin Pharmacol       Date:  2001-01       Impact factor: 4.335

Review 4.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

Review 5.  Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.

Authors:  L Ereshefsky; C Riesenman; Y W Lam
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

6.  Fluvoxamine dose-dependent interaction with haloperidol and the effects on negative symptoms in schizophrenia.

Authors:  Norio Yasui-Furukori; Tsuyoshi Kondo; Kazuo Mihara; Yoshimasa Inoue; Sunao Kaneko
Journal:  Psychopharmacology (Berl)       Date:  2003-09-04       Impact factor: 4.530
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.